Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Following sustained virological response (SVR) for chronic hepatitis C (CHC) infection, patients with advanced fibrosis require regular monitoring for hepatocellular carcinoma (HCC). The aspartate aminotransferase to platelet ratio index (APRI) is a simple noninvasive surrogate marker known to reflect fibrosis. Methods: We retrospectively analyzed 598 patients who achieved SVR with interferonbased therapy for CHC. Results: Over a median of 5.1 years of follow-up, there were eight patients diagnosed with HCC and a 5-year cumulative incidence rate of 1.3%. The median pretreatment APRI was 0.83, which decreased to 0.29 after achieving SVR (p<0.001). Both the pre- and posttreatment indices were associated with HCC development. The 5-year cumulative HCC incidence rates were 0% and 2.8% for patients with pretreatment APRI <1.0 and ≥1.0, respectively (p=0.001) and 0.8% and 12.8% for patients with posttreatment APRI <1.0 and ≥1.0, respectively (p<0.001). Pretreatment APRI at a cutoff of 1.0 had a 100% negative predictive value until 10 years after SVR. Conclusions: HCC development was observed among CHC patients who achieved SVR. The pre- and post-treatment APRI could stratify HCC risk, indicating that the APRI could be a useful marker to classify HCC risk in CHC patients who achieved SVR. However, given the small number of HCC patients, this finding warrants further validation.
Abstract
Background/Aims: Following sustained virological response (SVR) for chronic hepatitis C (CHC) infection, patients with advanced fibrosis require regular monitoring for hepatocellular carcinoma (HCC). The aspartate aminotransferase to platelet ratio index (APRI) is a simple noninvasive surrogate marker known to reflect fibrosis. Methods: We retrospectively analyzed 598 patients who achieved SVR with interferonbased therapy for CHC. Results: Over a median of 5.1 years of follow-up, there were eight patients diagnosed with HCC and a 5-year cumulative incidence rate of 1.3%. The median pretreatment APRI was 0.83, which decreased to 0.29 after achieving SVR (p<0.001). Both the pre- and posttreatment indices were associated with HCC development. The 5-year cumulative HCC incidence rates were 0% and 2.8% for patients with pretreatment APRI <1.0 and ≥1.0, respectively (p=0.001) and 0.8% and 12.8% for patients with posttreatment APRI <1.0 and ≥1.0, respectively (p<0.001). Pretreatment APRI at a cutoff of 1.0 had a 100% negative predictive value until 10 years after SVR. Conclusions: HCC development was observed among CHC patients who achieved SVR. The pre- and post-treatment APRI could stratify HCC risk, indicating that the APRI could be a useful marker to classify HCC risk in CHC patients who achieved SVR. However, given the small number of HCC patients, this finding warrants further validation.
참고문헌 (32)
- Lauer GM, "Hepatitis C virus infection", N Engl J Med, 345, pp.41~52 (2001)
- Seeff LB, "Natural history of chronic hepatitis C", Hepatology, 36(5 Suppl 1), pp.S35~S46 (2002)
- Strader DB, "Diagnosis, management, and treatment of hepatitis C", Hepatology, 39, pp.1147~1171 (2004)
- Fried MW, "Once-daily simeprevir (TMC435)with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study", Hepatology, 58, pp.1918~1929 (2013)
- Zeuzem S, "Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3", J Hepatol, 40, pp.993~999 (2004)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 20, pp.89~136 (2014)
- Morisco F, "Sustained virological response:a milestone in the treatment of chronic hepatitis C", World J Gastroenterol, 19, pp.2793~2798 (2013)
- "recommendations for testing, managing, and treating hepatitis C" (2014)[URL]
- Yoshida H, "Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C", Gut, 53, pp.425~430 (2004)
- Huang JF, "Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan", Aliment Pharmacol Ther, 25, pp.1029~1037 (2007)
- Sinn DH, "Disease progression and the risk factor analysis for chronic hepatitis C", Liver Int, 28, pp.1363~1369 (2008)
- Okanoue T, "Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group", J Hepatol, 30, pp.653~659 (1999)
- Papatheodoridis GV, "Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis", Aliment Pharmacol Ther, 15, pp.689~698 (2001)
- Yamashita N, "Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes", J Gastroenterol, 49, pp.1504~1513 (2014)
- Chang KC, "Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy", Br J Cancer, 109, pp.2481~2488 (2013)
- Khokhar N, "Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C", J Coll Physicians Surg Pak, 23, pp.699~702 (2013)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2014", J Hepatol, 61, pp.373~395 (2014)
- Rockey DC, "liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
- Schiavon Lde L, "Noninvasive diagnosis of liver fibrosis in chronic hepatitis C", World J Gastroenterol, 20, pp.2854~2866 (2014)
- Lin CS, "Retrospective evaluation of serum markers APRI and AST", ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma, 2008, pp.47, 569~575
- Shaheen AA, "Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review", Hepatology, 46, pp.912~921 (2007)
- Korean Liver Cancer Study Group and National Cancer Center, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- Lin ZH, "Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis", Hepatology, 53, pp.726~736 (2011)
- Morgan RL, "Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies", Ann Intern Med, 158(5 Pt 1), pp.329~337 (2013)
- Mashitani T, "Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report", Cases J, 2, pp.18~ (2009)
- Nojiri K, "Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10years after sustained virological response to interferon therapy", Oncol Lett, 1, pp.427~430 (2010)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Poynard T, "Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C", J Hepatol, 59, pp.675~683 (2013)
- Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- Tamori A, "Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus", Am J Gastroenterol, 100, pp.1748~1753 (2005)
- Zarski JP, "Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study", J Hepatol, 56, pp.55~62 (2012)